IN2015DN01448A - - Google Patents

Download PDF

Info

Publication number
IN2015DN01448A
IN2015DN01448A IN1448DEN2015A IN2015DN01448A IN 2015DN01448 A IN2015DN01448 A IN 2015DN01448A IN 1448DEN2015 A IN1448DEN2015 A IN 1448DEN2015A IN 2015DN01448 A IN2015DN01448 A IN 2015DN01448A
Authority
IN
India
Prior art keywords
rsv
infection
subject
nucleotide sequence
sequence encoding
Prior art date
Application number
Other languages
English (en)
Inventor
Cédric Cheminay
Robin Steigerwald
Paul Chaplin
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of IN2015DN01448A publication Critical patent/IN2015DN01448A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/065—Poxviridae, e.g. avipoxvirus
    • C07K14/07—Vaccinia virus; Variola virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18571—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN1448DEN2015 2012-08-01 2013-03-15 IN2015DN01448A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261678367P 2012-08-01 2012-08-01
EP12005594 2012-08-01
PCT/EP2013/055483 WO2014019718A1 (en) 2012-08-01 2013-03-15 Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine

Publications (1)

Publication Number Publication Date
IN2015DN01448A true IN2015DN01448A (ko) 2015-07-03

Family

ID=46614287

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1448DEN2015 IN2015DN01448A (ko) 2012-08-01 2013-03-15

Country Status (19)

Country Link
US (6) US9480738B2 (ko)
EP (2) EP3656396A1 (ko)
JP (2) JP6523955B2 (ko)
KR (3) KR102435054B1 (ko)
CN (2) CN109266622B (ko)
AU (1) AU2013298915B2 (ko)
BR (1) BR112015002131B1 (ko)
CA (2) CA3158572A1 (ko)
CY (1) CY1122717T1 (ko)
EA (2) EA031453B1 (ko)
HK (1) HK1205459A1 (ko)
IL (1) IL236744B (ko)
IN (1) IN2015DN01448A (ko)
MX (3) MX362511B (ko)
MY (1) MY171498A (ko)
NZ (1) NZ704005A (ko)
SG (1) SG11201500696VA (ko)
SI (1) SI2879702T1 (ko)
WO (1) WO2014019718A1 (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2879702T3 (da) * 2012-08-01 2020-02-24 Bavarian Nordic As Rekombinant modificeret vacciniavirus ankara (mva)-vaccine mod respiratorisk syncytialvirus (rsv)
CA2905569C (en) * 2013-03-15 2023-07-25 Bavarian Nordic A/S Single high dose of modified vaccinia virus ankara induces a protective immune response in neonates and infants
WO2015189425A1 (en) 2014-06-13 2015-12-17 Glaxosmithkline Biologicals Sa Immunogenic combinations
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
EA038402B9 (ru) 2015-06-12 2021-09-22 Глаксосмитклайн Байолоджикалс Са Аденовирусные полинуклеотиды и полипептиды
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
MX2019011869A (es) 2017-04-04 2020-01-09 Univ Washington Nanoestructuras proteicas auto-ensamblables que muestran proteinas f de paramixovirus y/o neumovirus y su uso.
AU2018269319A1 (en) 2017-05-15 2019-11-07 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
EP3624845A1 (en) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
BR112020012361A2 (pt) 2017-12-20 2020-11-24 Glaxosmithkline Biologicals S.A. constructos de antígeno do vírus epstein-barr
WO2019169120A1 (en) 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines
JP7437385B2 (ja) 2018-09-06 2024-02-22 バヴァリアン・ノルディック・アクティーゼルスカブ 保管が改善されたポックスウイルス組成物
US20220195016A1 (en) * 2019-04-18 2022-06-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Biological and synthetic molecules inhibiting respiratory syncytial virus infection
JP2022544414A (ja) * 2019-08-13 2022-10-18 アルティミューン インコーポレーティッド 治療剤の有効性及びその投与の経路
EP4117722A1 (en) 2020-03-12 2023-01-18 Bavarian Nordic A/S Compositions improving poxvirus stability
CA3230406A1 (en) 2021-09-03 2023-03-09 Jurgen Hausmann Utilization of micro-rna for downregulation of cytotoxic transgene expression by modified vaccinia virus ankara (mva)

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5149650A (en) 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
US5639853A (en) 1987-09-29 1997-06-17 Praxis Biologics, Inc. Respiratory syncytial virus vaccines
US5223254A (en) 1987-09-29 1993-06-29 Praxis Biologics, Inc. Respiratory syncytial virus: vaccines
AU617739B2 (en) 1987-12-23 1991-12-05 Pharmacia & Upjohn Company Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
US6730305B1 (en) 2000-05-08 2004-05-04 The Uab Research Foundation Nucleotide sequences encoding bovine respiratory syncytial virus immunogenic proteins
IE912586A1 (en) 1990-07-24 1992-01-29 Uab Research Foundation Bovine respiratory syncytial virus vaccines
GB9200117D0 (en) 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
US6077511A (en) 1994-08-25 2000-06-20 Instituut Voor Dierhouderij En Diergezondheid Antigenic peptide derived from the G protein of RSV for type- and subtype-specific diagnosis of respiratory syncytial virus (RSV) infection
FR2726471B1 (fr) 1994-11-07 1997-01-31 Pf Medicament Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
US6019980A (en) 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US6083925A (en) 1995-06-07 2000-07-04 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US6180398B1 (en) 1996-07-12 2001-01-30 Virogeneitics Corporation Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation
US6020182A (en) 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
US6699478B1 (en) 1997-09-19 2004-03-02 Wyeth Holdings Corporation Enhanced immune response to attachment (G) protein of Respiratory Syncytial Virus
FR2798857B1 (fr) * 1999-09-23 2003-06-06 Pf Medicament Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale
US6651655B1 (en) 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
SG106639A1 (en) 2000-10-10 2004-10-29 Gen Electric Apparatus and method for introducing small amounts of refractory elements into a vapor deposition coating
AU2002224416A1 (en) 2000-10-18 2002-04-29 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Compositions and methods for modulating RSV infection and immunity
EP1598425A1 (en) 2000-11-23 2005-11-23 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
CN101397574A (zh) 2001-12-04 2009-04-01 巴法里安诺迪克有限公司 黄病毒ns1亚单位疫苗
CN102703393A (zh) 2002-05-16 2012-10-03 巴法里安诺迪克有限公司 表达插入痘病毒基因组中的同源基因的重组痘病毒
US7368537B2 (en) 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
EP1768993A4 (en) 2004-06-16 2008-07-23 Univ Johns Hopkins CYSTEINE-RICH REGION OF SYNCYTIAL RESPIRATORY VIRUS AND METHODS OF USE THEREOF
EA010057B1 (ru) * 2004-08-27 2008-06-30 Панацея Биотек Лтд. Инактивированная полиомиелитная вакцина, полученная из штамма сейбина вируса полиомиелита
WO2008115199A2 (en) * 2006-08-18 2008-09-25 The University Of North Carolina At Chapel Hill Chimeric virus vaccines
US8772256B2 (en) * 2006-11-30 2014-07-08 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Codon modified immunogenic compositions and methods of use
DE102006060799A1 (de) 2006-12-21 2008-06-26 RUHR-UNIVERSITäT BOCHUM RSV F-Protein und seine Verwendung
EP2181121A4 (en) * 2007-03-21 2012-07-11 Id Biomedical Corp Quebec CHIMÄRE ANTIGENE
KR100938105B1 (ko) * 2007-09-21 2010-01-21 이화여자대학교 산학협력단 호흡기 신시치아 바이러스 백신
EP3109258B1 (en) 2007-12-24 2019-01-23 ID Biomedical Corporation of Quebec Recombinant rsv antigens
WO2010039224A2 (en) 2008-09-30 2010-04-08 University Of Massachusetts Medical School Respiratory syncytial virus (rsv) sequences for protein expression and vaccines
JP6046348B2 (ja) 2008-11-18 2016-12-14 タケダ ヴァクシーンズ， インコーポレイテッド Ｒｓｖｆｖｌｐならびにその製造および使用の方法
EP2352834B1 (en) 2008-11-21 2016-12-21 Bavarian Nordic A/S Vector comprising multiple homologous nucleotide sequences
DK3067064T3 (da) 2008-12-09 2020-06-08 Novavax Inc Modificerede rsv-f-proteiner og fremgangsmåder til anvendelse deraf
US20110318376A1 (en) 2008-12-24 2011-12-29 University Of Rochester Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins
DK2445526T3 (en) 2009-06-24 2016-06-27 Glaxosmithkline Biologicals Sa Recombinant RSV antigens.
EA201270062A1 (ru) 2009-06-24 2013-02-28 АйДи БАЙОМЕДИКАЛ КОРПОРЕЙШН ОФ КВЕБЕК Вакцина
US20120164176A1 (en) * 2009-07-15 2012-06-28 Kurt Swanson Rsv f protein compositions amd methods for making same
US8846056B2 (en) 2009-08-04 2014-09-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control Anti-RSV immunogens and methods of immunization
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
US20110097358A1 (en) 2009-10-12 2011-04-28 Techno Vax, Inc. RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs)
WO2011057401A1 (en) 2009-11-12 2011-05-19 Trojan Technologies Cleaning apparatus. radiation source module and fluid treatment system
CA2786333C (en) 2010-01-28 2018-03-20 Bavarian Nordic A/S Vaccinia virus mutants containing the major genomic deletions of mva
BR112013000345B1 (pt) * 2010-07-07 2021-11-23 Artificial Cell Technologies, Inc Composição compreendendo partículas contendo epítopos de rsv
WO2012089536A1 (en) * 2010-12-17 2012-07-05 Philip Morris Products S.A. Container having interacting surface elements including a relief element
WO2012085936A2 (en) * 2010-12-20 2012-06-28 Panacea Biotech Ltd Recombinant respiratory syncytial virus plasmids and vaccines
WO2012089231A1 (en) 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines

Also Published As

Publication number Publication date
CN104540520A (zh) 2015-04-22
MY171498A (en) 2019-10-15
US20200171142A1 (en) 2020-06-04
BR112015002131A8 (pt) 2022-08-23
KR20150038431A (ko) 2015-04-08
US20150209421A1 (en) 2015-07-30
CN109266622B (zh) 2023-05-09
NZ704005A (en) 2016-07-29
MX2023003746A (es) 2023-04-24
EA031453B1 (ru) 2019-01-31
US10532094B2 (en) 2020-01-14
EP2879702B1 (en) 2019-11-27
EP2879702A1 (en) 2015-06-10
CN109266622A (zh) 2019-01-25
EA201891945A2 (ru) 2019-01-31
SG11201500696VA (en) 2015-02-27
IL236744B (en) 2022-04-01
WO2014019718A1 (en) 2014-02-06
CA2879915C (en) 2022-07-05
AU2013298915A1 (en) 2015-02-19
US20170043008A1 (en) 2017-02-16
KR20220119527A (ko) 2022-08-29
EA201891945A3 (ru) 2019-05-31
EP2879702B9 (en) 2020-02-26
MX2015001479A (es) 2015-08-12
US10124058B2 (en) 2018-11-13
EP3656396A1 (en) 2020-05-27
HK1205459A1 (en) 2015-12-18
US9480738B2 (en) 2016-11-01
KR102264852B1 (ko) 2021-06-14
CA3158572A1 (en) 2014-02-06
CN104540520B (zh) 2018-10-23
JP2023139095A (ja) 2023-10-03
AU2013298915B2 (en) 2018-03-01
BR112015002131A2 (pt) 2017-11-07
MX2019000933A (es) 2022-06-27
BR112015002131B1 (pt) 2022-11-01
US20170326228A1 (en) 2017-11-16
JP2015524660A (ja) 2015-08-27
US20190117764A1 (en) 2019-04-25
CY1122717T1 (el) 2021-03-12
IL236744A0 (en) 2015-02-26
US20210196814A1 (en) 2021-07-01
KR102435054B1 (ko) 2022-08-22
EA201590304A1 (ru) 2015-06-30
JP6523955B2 (ja) 2019-06-05
MX362511B (es) 2019-01-22
KR20210072144A (ko) 2021-06-16
US10946089B2 (en) 2021-03-16
CA2879915A1 (en) 2014-02-06
SI2879702T1 (sl) 2020-02-28
US9717787B2 (en) 2017-08-01

Similar Documents

Publication Publication Date Title
MX2023003746A (es) Vacuna del virus vaccinia ankara modificado (mva) recombinante para virus sincicial respiratorio (vsr).
WO2016109792A8 (en) Novel multivalent nanoparticle-based vaccines
NZ630753A (en) Vaccine against rsv
MX2017002791A (es) Vacuna contra filovirus de virus vaccinia ankara modificado (mva) recombinante.
MX350274B (es) Vacunas para hsv-2.
EA201390866A1 (ru) Филовирусные вакцины на основе аденовирусов серотипа 26 и серотипа 35
MX2014009845A (es) Vectores poxvirales recombinantes que expresan proteinas tanto de rabia como de ox40, y vacunas hechas a partir de los mismos.
MY180109A (en) Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
ZA201707985B (en) Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine
WO2012106231A3 (en) Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses
MX345150B (es) Antigenos ampliamente reactivos computacionalmente optimizados para virus de influenza h5n1 y h1n1.
MX2019003682A (es) Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas.
CA2863981A1 (en) Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
PH12014501388A1 (en) A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv
EP2552490A4 (en) INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF
CO6700818A2 (es) Vectores de parapoxvirus
AU2013352179A8 (en) Computationally optimized broadly reactive antigens for H1N1 influenza
CO6670515A2 (es) Vectores de parapoxvirus
NZ704188A (en) Attenuated swine influenza vaccines and methods of making and use thereof
EA033242B1 (ru) Усовершенствованные нуклеиновые кислоты и белки вируса человеческой папилломы, вакцины и композиции на их основе и способы индукции иммунного ответа против впч с их применением
WO2013093514A3 (en) Vaccines - peptides
EA201992602A2 (ru) Вакцины против впг-2
WO2012064816A3 (en) Methods of neutralizing viral infection
NZ626124A (en) Vaccines against hpv